Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 11/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 10/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 4/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.34 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.34 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.34 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7933956 | 1.00 | SCN3A (0.37) | SCN3ASCN4ADRD2HTRA1KDM5A | |
| SCHEMBL12552765 | 0.94 | DRD2 (0.37) | SCN3ASCN4ADRD2HTRA1KDM5A | |
| SCHEMBL7947251 | 0.92 | HTRA1 (0.36) | SCN3ASCN4ADRD2HTRA1KDM5A | |
| SCHEMBL1930657 | 0.92 | HTRA1 (0.36) | SCN3ASCN4ADRD2HTRA1KDM5A | |
| SCHEMBL19856956 | 0.92 | HTRA1 (0.36) | SCN3ASCN4ADRD2HTRA1KDM5A | |
| SCHEMBL19856962 | 0.91 | STAT6 (0.35) | SCN3ASCN4ADRD2HTRA1KDM5A | |
| SCHEMBL19856958 | 0.91 | STAT6 (0.35) | SCN3ASCN4ADRD2HTRA1KDM5A | |
| SCHEMBL7934666 | 0.91 | DRD2 (0.40) | SCN3ASCN4ADRD2HTRA1DRD3 | |
| SCHEMBL19856859 | 0.90 | CYP51A1 (0.40) | DRD2HTRA1KDM5ASTAT6CYP51A1 | |
| SCHEMBL1550050 | 0.90 | CYP51A1 (0.40) | DRD2HTRA1KDM5ASTAT6CYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| WO-2010011914-A1 | TRPV4 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130400-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV1 | SCN3A 411/4885SCN4A 53/4885DRD2 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.